DANAHER CORP (1DHR.MI) Stock Price & Overview
BIT:1DHR • US2358511028
Current stock price
The current stock price of 1DHR.MI is 162.58 EUR. Today 1DHR.MI is down by -10.93%.
1DHR.MI Key Statistics
- Market Cap
- 114.967B
- P/E
- 24.09
- Fwd P/E
- 22.12
- EPS (TTM)
- 6.75
- Dividend Yield
- 0.84%
1DHR.MI Stock Performance
1DHR.MI Stock Chart
1DHR.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1DHR.MI.
1DHR.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1DHR.MI. 1DHR.MI is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
1DHR.MI Earnings
On January 28, 2026 1DHR.MI reported an EPS of 2.23 and a revenue of 6.84B. The company beat EPS expectations (2.56% surprise) and missed revenue expectations (-0.52% surprise).
1DHR.MI Forecast & Estimates
30 analysts have analysed 1DHR.MI and the average price target is 225.38 EUR. This implies a price increase of 38.63% is expected in the next year compared to the current price of 162.58.
For the next year, analysts expect an EPS growth of 8.87% and a revenue growth 4.44% for 1DHR.MI
1DHR.MI Groups
Sector & Classification
1DHR.MI Financial Highlights
Over the last trailing twelve months 1DHR.MI reported a non-GAAP Earnings per Share(EPS) of 6.75. The EPS increased by 4.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.71% | ||
| ROA | 4.33% | ||
| ROE | 6.88% | ||
| Debt/Equity | 0.35 |
1DHR.MI Ownership
1DHR.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 56S1 | SARTORIUS STEDIM BIOTECH | 33.09 | 16.585B | ||
| DIM | SARTORIUS STEDIM BIOTECH | 32.78 | 16.575B | ||
| SRT3 | SARTORIUS AG-VORZUG | 37.06 | 16.054B | ||
| SRT | SARTORIUS AG | 29.41 | 12.64B | ||
| QIA | QIAGEN N.V. | 15.66 | 7.222B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 12.54 | 2.096B | ||
| EVT | EVOTEC SE | N/A | 805.796M | ||
| GXI | GERRESHEIMER AG | 6.63 | 589.598M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 13.97 | 187.51M | ||
| ALECR | EUROFINS CEREP-REGR | N/A | 158M | ||
| MLC | MALIN CORP PLC | N/A |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1DHR.MI
Company Profile
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 58,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Company Info
IPO: 1969-12-10
DANAHER CORP
2200 Pennsylvania Ave NW Ste 800W
WASHINGTON WASHINGTON DC US
Employees: 62000
Phone: 18667611444
DANAHER CORP / 1DHR.MI FAQ
What does DANAHER CORP do?
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 58,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
What is the current price of 1DHR stock?
The current stock price of 1DHR.MI is 162.58 EUR. The price decreased by -10.93% in the last trading session.
Does DANAHER CORP pay dividends?
DANAHER CORP (1DHR.MI) has a dividend yield of 0.84%. The yearly dividend amount is currently 1.07.
How is the ChartMill rating for DANAHER CORP?
1DHR.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What sector and industry does DANAHER CORP belong to?
DANAHER CORP (1DHR.MI) operates in the Health Care sector and the Life Sciences Tools & Services industry.
Can you provide the growth outlook for DANAHER CORP?
The Revenue of DANAHER CORP (1DHR.MI) is expected to grow by 4.44% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.